History
# Registration date Revision Id
2 2021-09-28, 1400/07/06 199706
1 2021-03-10, 1399/12/20 174618
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    Determining the effect of flavonoid content of Mangifera indica leaf extract by prescribing capsules containing 100 mg of extract on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients under home care
    Determining the effect of ZAX.1399.C03 on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients in home care
    تعیین میزان اثر محتوای فلاونوئیدی عصاره برگ گیاه Mangifera indica با تجویز کپسول حاوی 100 میلی گرم عصاره بر سیر بیماری، درمان علامتی و کاهش واسطه های التهابی مبتلایان COVID-19 تحت مراقبت در منزل
    تعیین میزان اثر ZAX.1399.C03 بر سیر بیماری، درمان علامتی و کاهش واسطه های التهابی مبتلایان COVID-19 تحت مراقبت در منزل
    The double-blind clinical trial, two treatment groups and parallel control, The stage will be over 60 patients. For randomization, we will use the method of permutation blocks with a number of 6 blocks using Random allocation software.
    The triple blind clinical trial, two treatment groups and parallel control, The stage will be over 60 patients. For randomization, we will use the method of permutation blocks with a number of 6 blocks using Random allocation software.
    کارآزمایی بالینی دوسویه کور ، دو گروه درمانی و کنترل به صورت موازی، مرحله بر روی 60 بیمار خواهد بود. برای تصادفی سازی از روش بلاک های جایگشتی با تعداد بلاک های 6 تایی با استفاده از نرم افزار Random allocation software استفاده خواهیم کرد.
    کارآزمایی بالینی سه سویه کور ، دو گروه درمانی و کنترل به صورت موازی، مرحله بر روی 60 بیمار خواهد بود. برای تصادفی سازی از روش بلاک های جایگشتی با تعداد بلاک های 6 تایی با استفاده از نرم افزار Random allocation software استفاده خواهیم کرد.
    Patients with COVID19 under home care are divided into groups A and B. The anti-inflammatory effects of mango leaf extract will be evaluated with 100 mg capsules. The study will be blinded at the level of outcome assessor and statistical analyst of results. Location: Fasa University of Medical Sciences
    Patients with COVID19 in home care are divided into groups A and B. The anti-inflammatory effects of ZAX.1399.C03 evaluated. The study will be blinded at the level of outcome assessor and statistical analyst of results. Location: Fasa University of Medical Sciences
    بیماران مبتلا به COVID19 تحت مراقبت در منزل به دو گروه AوB، تقسیم می شوند. اثرات ضد التهابی عصاره برگ انبه با کپسول های 100 میلی گرمی، مورد ارزیابی خواهد بود. مطالعه در سطح ارزیابی کننده ی پیامد و تحلیل کننده ی آماری نتایج، کور خواهد شد. محل انجام: دانشگاه علوم پزشکی فسا
    بیماران مبتلا به COVID19 تحت مراقبت در منزل به دو گروه AوB، تقسیم می شوند. اثرات ضد التهابی ZAX.1399.C03، مورد ارزیابی خواهد بود. مطالعه در سطح ارزیابی کننده ی پیامد و تحلیل کننده ی آماری نتایج، کور خواهد شد. محل انجام: دانشگاه علوم پزشکی فسا
    Admission requirements: Definitive diagnosis of COVID-19 2. Age over 18 years 3. Both sexes (male and female) 4. Having informed and written consent to participate in the study 5. No history of any allergies 6. Do not take anticoagulants 7. Not getting pregnant and breastfeeding 8. No diabetes in the person Conditions for not entering the study: 1. Disagreement of the physician in charge of the patient 2. History of any allergies 3. History of heart and kidney disease 4. Patient dissatisfaction 5. History of high blood pressure
    Admission requirements: 1. Definitive diagnosis of COVID-19 2. Age over 18 years 3. Both sexes (male and female) 4. Having informed and written consent to participate in the study 5. No history of any allergies 6. Do not take anticoagulants 7. Not getting pregnant and breastfeeding 8. No diabetes in the person Conditions for not entering the study: 1. Disagreement of the physician in charge of the patient 2. History of any allergies 3. History of heart and kidney disease 4. Patient disagreement 5. History of high blood pressure
    Divide patients into two similar groups A and B. The treatment group contains capsules containing 100 mg of plant leaf extract (Mangifera indica) and the placebo group contains 100 mg capsules containing fried corn flour. By introducing the plan and justifying the patient, written consent is received.
    Divide patients into two similar groups A and B. The treatment group contains capsules containing ZAX.1399.C03 and the placebo group contains capsules containing fried corn flour. By introducing the plan and justifying the patient, written consent is received.
    تقسیم بیماران در دو دسته مشابه A و B. گروه درمان کپسول حاوی 100 میلی گرم عصاره برگ گیاه (Mangifera indica) و گروه دارونما کپسول 100 میلی گرمی حاوی آرد ذرت بوداده. با معرفی طرح و توجیه بیمار انجام می شود، رضایت کتبی دریافت می گردد.
    تقسیم بیماران در دو دسته مشابه A و B. گروه درمان کپسول حاوی ZAX.1399.C03 و گروه دارونما کپسول حاوی آرد ذرت بوداده. با معرفی طرح و توجیه بیمار انجام می شود، رضایت کتبی دریافت می گردد.
    1. hospitalization in medical centers with natural activity 2. Degree of hemoglobin saturation (SPO2) in the normal range
    1. Serum levels of inflammatory mediators IL6 2. Degree of hemoglobin saturation (SPO2) in the normal range
    1. بستری در مراکز درمانی با فعالیت طبیعی 2. درجه اشباع هموگلبین (SPO2) در محدوده طبیعی
    1. سطح سرمی واسطه التهابی IL6 2. درجه اشباع هموگلبین (SPO2) در محدوده طبیعی
  • General information

    Double blinded
    Triple blinded
    1
    1
    empty
    1. In order to protect the intellectual property of the project, the name of the studied plant product has been removed and the phrase ZAX.1399.C03 has been replaced. 2. The English translation sections have been revised from a grammatical point of view and "minor" changes have been made. 3. The main outcome variable is described in the abstract of serum IL6 level and the degree of hemoglobin saturation of the blood.
    empty
    1. در جهت حفظ مالکیت معنوی پروژه، نام فراورده گیاهی مورد مطالعه حذف و عبارت ZAX.1399.C03 جایگزین آن شده است. 2. قسمت های ترجمه به زبان انگلیسی از دیدگاه دستور زبان مجددا بازبینی شده و تغییراتی "جزئی" اعمال شده است. 3. متغیر پیامد اصلی در قسمت چکیده سطح سرمی IL6 و درجه اشباع هموگلبین خون عنوان شده است.
    Control of inflammatory process in patients with coronavirus affected by polyflavonoid extract of Mangifera indica leaf
    Control of inflammatory process in patients with coronavirus affected by ZAX.1399.C03
    کنترل فرایند التهاب در بیماران مبتلا به کروناویروس تحت تاثیر عصاره پلی فلاونوئیدی برگ انبه
    کنترل فرایند التهاب در بیماران مبتلا به کروناویروس تحت تاثیر ZAX.1399.C03
    Evaluation of anti-inflammatory effect of flavonoid content of Mango leaf extract (Mangifera indica) on inflammation of airways in patients with coronavirus under home care
    Evaluation of anti-inflammatory effect of ZAX.1399.C03 on airways inflammation in patients with coronavirus in home care
    بررسی اثر ضد التهابی محتوای فلاونوئیدی عصاره برگ انبه (Mangifera indica) بر التهاب مجاری تنفسی بیماران مبتلا به کروناویروس تحت مراقبت در منزل
    بررسی اثر ضد التهابی ZAX.1399.C03 بر التهاب مجاری تنفسی بیماران مبتلا به کروناویروس تحت مراقبت در منزل
    Diagnosis of COVID-19 is detected by a laboratory diagnostic kit from a patient's sputum or CT scan
    Age over 18 years
    Both sexes (male and female)
    Having informed and written consent to participate in the study
    No history of any allergies
    No uncontrolled hypertension
    Do not take anticoagulants (aspirin, Plavix, warfarin)
    Not getting pregnant and breastfeeding
    No diabetes in the person
    COVID-19 is detected by PCR laboratory diagnostic kit
    Age over 18 years
    Both sexes (male and female)
    Having informed and written consent to participate in the study
    No history of any allergies
    No uncontrolled hypertension
    Do not take anticoagulants (aspirin, Plavix, warfarin)
    Not pregnant and breastfeeding
    No diabetes in the person
    تشخیص بیماریCOVID-19 به وسیله کیت تشخیصی آزمایشگاهی از روی خلط ریه بیمار یا سی تی اسکن، آشکار شده باشد.
    سن بالای 18سال
    هردو جنس (مرد و زن)
    داشتن رضایت آگاهانه وکتبی جهت شرکت در مطالعه
    عدم سابقه هیچ گونه حساسیت
    نداشتن بیماری فشارخون بالای کنترل نشده
    عدم مصرف داروهای ضد انعقادی(آسپرین،پلاویکس،وارفارین)
    عدم بارداری و شیردهی
    عدم وجود دیابت در فرد
    تشخیص بیماریCOVID-19 به وسیله کیت تشخیصی آزمایشگاهی PCR
    سن بالای 18سال
    هردو جنس (مرد و زن)
    داشتن رضایت آگاهانه وکتبی جهت شرکت در مطالعه
    عدم سابقه هیچ گونه حساسیت
    نداشتن بیماری فشارخون بالای کنترل نشده
    عدم مصرف داروهای ضد انعقادی(آسپرین،پلاویکس،وارفارین)
    عدم بارداری و شیردهی
    عدم وجود دیابت در فرد
    Disagreement of the responsible physician of the patient before randomization
    History of any allergies to drugs, various substances, food and ...
    History of liver and kidney disease
    Patient dissatisfaction
    Inability of the patient to take the drug for any reason
    History of hypertension and heart disease
    Disagreement of the responsible physician of the patient before randomization
    History of any allergies to drugs, various substances, food and ...
    History of liver and kidney disease
    Patient disagreement
    Inability of the patient to take the drug for any reason
    History of hypertension and heart disease
    This study is performed on patients referred to health centers and infectious disease specialists in the present study. For patients under home care, the hospital code along with the relevant information (medication regimen, age and sex, severity of the disease and severity of symptoms) is provided by the expert to the patient. The relevant expert divides the patients into two similar groups based on the treatment regimen, age group, sex, severity of the disease and symptoms, and randomly divides one group into group A and one group into group B using the patient code numbers. For randomization, the permutation block method with the number of blocks of 6 is done using Random allocation software.
    This study is performed on patients referred to health centers and infectious disease specialists in the present study. For home care patients, the admit code along with the relevant information (medication regimen, age and sex, severity of the disease and severity of symptoms) is provided by the expert to the patient. The relevant expert divides the patients into two similar groups based on the treatment regimen, age group, sex, severity of the disease and symptoms, and randomly divides one group into group A and one group into group B using the patient code numbers. For randomization, the permutation block method with the number of blocks of 6 is done using Random allocation software.
    این مطالعه، بر بیماران مراجعه کننده به مراکز بهداشتی و متخصصین عفونی همکار در مطالعه پیش رو صورت می پذیرد. برای بیماران تحت مراقبت در منزل،کد بستری به همراه اطلاعات مربوطه (رژیم دارویی، سن و جنس و شدت بیماری و شدت علائم) توسط کارشناس برای بیمار منظور می شود. کارشناس مربوطه بیماران را براساس رژیم درمانی، گروه سنی، جنسیت، شدت بیماری و علائم، به دو دسته مشابه تقسیم می کند و به صورت تصادفی و با استفاده از شماره کدهای بیمار، یک گروه را گروه A و یک گروه را گروه B قرار می دهد. برای تصادفی سازی از روش بلاک های جایگشتی با تعداد بلاک های 6 تایی با استفاده از نرم افزار Random allocation software انجام می گیرد.
    این مطالعه، بر بیماران مراجعه کننده به مراکز بهداشتی و متخصصین عفونی همکار در مطالعه پیش رو صورت می پذیرد. برای بیماران تحت مراقبت در منزل،کد پذیرش به همراه اطلاعات مربوطه (رژیم دارویی، سن و جنس و شدت بیماری و شدت علائم) توسط کارشناس برای بیمار منظور می شود. کارشناس مربوطه بیماران را براساس رژیم درمانی، گروه سنی، جنسیت، شدت بیماری و علائم، به دو دسته مشابه تقسیم می کند و به صورت تصادفی و با استفاده از شماره کدهای بیمار، یک گروه را گروه A و یک گروه را گروه B قرار می دهد. برای تصادفی سازی از روش بلاک های جایگشتی با تعداد بلاک های 6 تایی با استفاده از نرم افزار Random allocation software انجام می گیرد.
    For blinding, the study of the drug (capsules containing 100 mg of Mangifera indica leaf extract ) and placebo (including roasted corn flour capsules) with the names A and B in the same package are prescribed by the doctor to the patient.) Capsules according to The principles of pharmacy are created by a pharmacist.) A patient-level study, outcome evaluator, and statistical analyst of the results will be blind. Only the manufacturer of the drug can decode the contents of each capsule based on the original retained form of the randomization results The person in charge of drug delivery and the patient, the doctor, the person in charge of evaluating the consequences will not be aware of the coding. The results of the two groups under the headings of groups A and B will be delivered to the statistical analyzer.
    For blinding, the study of the drug and placebo with the names A and B in the same package are prescribed by the doctor to the patient. (Capsules according to The principles of pharmacy are created by a pharmacist.) A patient-level study, outcome evaluator, and statistical analyst of the results will be blind. Only the manufacturer of the drug can decode the contents of each capsule based on the original retained form of the randomization results The person in charge of drug delivery and the patient, the doctor, the person in charge of evaluating the consequences will not be aware of the coding. The results of the two groups under the headings of groups A and B will be delivered to the statistical analyzer.
    برای کورسازی مطالعه دارو (کپسول حاوی 100 میلی گرم عصاره برگ گیاه (Mangifera indica و دارونما (شامل کپسول آرد ذرت بوداده) با نام های A وB در بسته بندی یکسان نام گذاری شده اند توسط پزشک به بیمار تجویز می گردد. (کپسول ها مطابق اصول داروسازی توسط متخصص داروساز ایجاد می شود.) مطالعه در سطح بیمار، ارزیابی کننده ی پیامد و تحلیل کننده ی آماری نتایج، کور خواهد شد. تنها سازنده دارو بر اساس فرم اوليه نگهداري شده ي نتايج راندوميزاسيون مي تواند از محتواي هرکپسول رمز گشايي کند. مسئول تحويل دارو و بيمار، پزشک، مسئول ارزيابي پيامدها از کدبندي ها اطلاع نخواهند داشت. نتايج دو گروه تحت عناوين گروه A و B به تحليل کننده ي آماري تحويل داده خواهد شد.
    برای کورسازی مطالعه، دارو و دارونما با نام های A وB در بسته بندی یکسان نام گذاری شده اند توسط پزشک به بیمار تجویز می گردد. (کپسول ها مطابق اصول داروسازی توسط متخصص داروساز ایجاد می شود.) مطالعه در سطح بیمار، ارزیابی کننده ی پیامد و تحلیل کننده ی آماری نتایج، کور خواهد شد. تنها سازنده دارو بر اساس فرم اوليه نگهداري شده ي نتايج راندوميزاسيون مي تواند از محتواي هرکپسول رمز گشايي کند. مسئول تحويل دارو و بيمار، پزشک، مسئول ارزيابي پيامدها از کدبندي ها اطلاع نخواهند داشت. نتايج دو گروه تحت عناوين گروه A و B به تحليل کننده ي آماري تحويل داده خواهد شد.
  • Intervention groups

    #1
    Intervention group: The medicinal composition of mango leaf polyflavonoid extract, in the form of capsules weighing 100 mg of dry extract, in two daily doses, is consumed for 7 to 14 days.
    Intervention group: The medicinal composition of ZAX.1399.C03 in two daily doses, is consumed for 7 to 14 days.
    گروه مداخله: ترکیب دارویی عصاره پلی فلاونوئیدی برگ انبه، در شکل دارویی کپسول با وزن 100 میلی گرم عصاره خشک، به میزان دو دوز روزانه، در مدت زمان 7 الی 14 روز مصرف می شود.
    گروه مداخله: ترکیب دارویی ZAX.1399.C03، به میزان دو دوز روزانه، در مدت زمان 7 الی 14 روز مصرف می شود.
    #2
    Control group: The composition of popcorn flour is consumed in the form of capsules weighing 100 mg of flour, in two daily doses, for a period of 7 to 14 days.
    Control group: The composition of popcorn flour is consumed, in two daily doses, for a period of 7 to 14 days.
    گروه کنترل: ترکیب آرد بو داده ذرت، در شکل دارویی کپسول با وزن 100 میلی گرم از آرد، به میزان دو دوز روزانه، در مدت زمان 7 الی 14 روز مصرف می شود.
    گروه کنترل: ترکیب آرد بو داده ذرت، به میزان دو دوز روزانه، در مدت زمان 7 الی 14 روز مصرف می شود.
  • Sponsors / Funding sources

    #1

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Dr. Mojtaba Farjam
    Full name of responsible person - Persian: دکتر مجتبی فرجام
    Street address - English: Ibn Sina square, Fasa city,
    Street address - Persian: شهرستان فسا، میدان ابن سینا
    City - English: Fasa
    City - Persian: فسا
    Province: Fars
    Country: Iran (Islamic Republic of)
    Postal code: 7461686688
    Phone: +98 71 5335 0994
    Fax: +98 71 5335 7091
    Email: kouhpayeha@gmail.com
    Web page address: https://www.fums.ac.ir/

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Dr. Mojtaba Farjam
    Full name of responsible person - Persian: دکتر مجتبی فرجام
    Street address - English: Ibn Sina square, Fasa city,
    Street address - Persian: شهرستان فسا، میدان ابن سینا
    City - English: Fasa
    City - Persian: فسا
    Province: Fars
    Country: Iran (Islamic Republic of)
    Postal code: 7461686688
    Phone: +98 71 5335 0994
    Fax: +98 71 5335 7091
    Email: farjam.md@gmail.com
    Web page address: https://www.fums.ac.ir/

Protocol summary

Study aim
Determining the effect of ZAX.1399.C03 on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients in home care
Design
The triple blind clinical trial, two treatment groups and parallel control, The stage will be over 60 patients. For randomization, we will use the method of permutation blocks with a number of 6 blocks using Random allocation software.
Settings and conduct
Patients with COVID19 in home care are divided into groups A and B. The anti-inflammatory effects of ZAX.1399.C03 evaluated. The study will be blinded at the level of outcome assessor and statistical analyst of results. Location: Fasa University of Medical Sciences
Participants/Inclusion and exclusion criteria
Admission requirements: 1. Definitive diagnosis of COVID-19 2. Age over 18 years 3. Both sexes (male and female) 4. Having informed and written consent to participate in the study 5. No history of any allergies 6. Do not take anticoagulants 7. Not getting pregnant and breastfeeding 8. No diabetes in the person Conditions for not entering the study: 1. Disagreement of the physician in charge of the patient 2. History of any allergies 3. History of heart and kidney disease 4. Patient disagreement 5. History of high blood pressure
Intervention groups
Divide patients into two similar groups A and B. The treatment group contains capsules containing ZAX.1399.C03 and the placebo group contains capsules containing fried corn flour. By introducing the plan and justifying the patient, written consent is received.
Main outcome variables
1. Serum levels of inflammatory mediators IL6 2. Degree of hemoglobin saturation (SPO2) in the normal range

General information

Reason for update
1. In order to protect the intellectual property of the project, the name of the studied plant product has been removed and the phrase ZAX.1399.C03 has been replaced. 2. The English translation sections have been revised from a grammatical point of view and "minor" changes have been made. 3. The main outcome variable is described in the abstract of serum IL6 level and the degree of hemoglobin saturation of the blood.
Acronym
SICF (مطالعه التهاب و کرونا ویروس فسا)
IRCT registration information
IRCT registration number: IRCT20210218050404N1
Registration date: 2021-03-10, 1399/12/20
Registration timing: prospective

Last update: 2021-09-30, 1400/07/08
Update count: 1
Registration date
2021-03-10, 1399/12/20
Registrant information
Name
Amin Dakhili Ardestani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 5335 9507
Email address
a.dakhili@fums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-06-21, 1400/03/31
Expected recruitment end date
2023-06-21, 1402/03/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of anti-inflammatory effect of ZAX.1399.C03 on airways inflammation in patients with coronavirus in home care
Public title
Control of inflammatory process in patients with coronavirus affected by ZAX.1399.C03
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
COVID-19 is detected by PCR laboratory diagnostic kit Age over 18 years Both sexes (male and female) Having informed and written consent to participate in the study No history of any allergies No uncontrolled hypertension Do not take anticoagulants (aspirin, Plavix, warfarin) Not pregnant and breastfeeding No diabetes in the person
Exclusion criteria:
Disagreement of the responsible physician of the patient before randomization History of any allergies to drugs, various substances, food and ... History of liver and kidney disease Patient disagreement Inability of the patient to take the drug for any reason History of hypertension and heart disease
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
  • Care provider
  • Outcome assessor
  • Data analyser
  • Data and Safety Monitoring Board
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
This study is performed on patients referred to health centers and infectious disease specialists in the present study. For home care patients, the admit code along with the relevant information (medication regimen, age and sex, severity of the disease and severity of symptoms) is provided by the expert to the patient. The relevant expert divides the patients into two similar groups based on the treatment regimen, age group, sex, severity of the disease and symptoms, and randomly divides one group into group A and one group into group B using the patient code numbers. For randomization, the permutation block method with the number of blocks of 6 is done using Random allocation software.
Blinding (investigator's opinion)
Triple blinded
Blinding description
For blinding, the study of the drug and placebo with the names A and B in the same package are prescribed by the doctor to the patient. (Capsules according to The principles of pharmacy are created by a pharmacist.) A patient-level study, outcome evaluator, and statistical analyst of the results will be blind. Only the manufacturer of the drug can decode the contents of each capsule based on the original retained form of the randomization results The person in charge of drug delivery and the patient, the doctor, the person in charge of evaluating the consequences will not be aware of the coding. The results of the two groups under the headings of groups A and B will be delivered to the statistical analyzer.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Fasa University of Medical Sciences
Street address
Fasa city, Ibn Sina square
City
Fasa
Province
Fars
Postal code
7461686688
Approval date
2021-02-06, 1399/11/18
Ethics committee reference number
IR.FUMS.REC.1399.156

Health conditions studied

1

Description of health condition studied
Incidence of inflammation due to the mechanism of COVID19
ICD-10 code
U07.1
ICD-10 code description
COVID-19

Primary outcomes

1

Description
Inflammatory mediators of IL6
Timepoint
Before the intervention and seven days after the start of consumption of mango leaf extract
Method of measurement
ELISA test

2

Description
Dry cough
Timepoint
Daily
Method of measurement
Check list

3

Description
Sputum cough
Timepoint
Daily
Method of measurement
Check list

4

Description
Shortness of breath
Timepoint
Daily
Method of measurement
Check list

5

Description
Gastrointestinal manifestations
Timepoint
Daily
Method of measurement
Check list

6

Description
Fever
Timepoint
Daily
Method of measurement
Check list

7

Description
Muscle and joint pain
Timepoint
Daily
Method of measurement
Check list

8

Description
Fatigue and laziness
Timepoint
Daily
Method of measurement
Check list

9

Description
Shiver
Timepoint
Daily
Method of measurement
Check list

10

Description
Odor and taste activity
Timepoint
Daily
Method of measurement
Check list

Secondary outcomes

1

Description
hospitalization in medical centers with normal activity
Timepoint
daily
Method of measurement
Check list

Intervention groups

1

Description
Intervention group: The medicinal composition of ZAX.1399.C03 in two daily doses, is consumed for 7 to 14 days.
Category
Treatment - Drugs

2

Description
Control group: The composition of popcorn flour is consumed, in two daily doses, for a period of 7 to 14 days.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Vali Asr Hospital, Fasa city
Full name of responsible person
Dr. Seyyed Amin Kouhpayeh
Street address
Ibn Sina square, Fasa city,
City
Fasa
Province
Fars
Postal code
4737774617
Phone
+98 71 5331 5011
Fax
+98 71 5331 4021
Email
kouhpayeha@gmail.com
Web page address
http://vh.fums.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Dr. Mojtaba Farjam
Street address
Ibn Sina square, Fasa city,
City
Fasa
Province
Fars
Postal code
7461686688
Phone
+98 71 5335 0994
Fax
+98 71 5335 7091
Email
farjam.md@gmail.com
Web page address
https://www.fums.ac.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Fasa University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Amin Dakhili Ardestani
Position
Student
Latest degree
Bachelor
Other areas of specialty/work
Anesthesiology
Street address
Fasa city, Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
7461686688
Phone
+98 71 5335 0996
Fax
+98 71 5335 7091
Email
a.dakhili@fums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Seyyed Amin Kouhpayeh
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Fasa city, Ibn Sina Square
City
Fasa
Province
Fars
Postal code
7461686688
Phone
+98 71 5335 0996
Fax
+98 71 5335 7091
Email
kouhpayeha@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Amin Dakhili Ardestani
Position
Student
Latest degree
Bachelor
Other areas of specialty/work
Anesthesiology
Street address
Fasa city, Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
7461686688
Phone
+98 71 5335 0996
Fax
+98 71 5335 7091
Email
a.dakhili@fums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Some of the information obtained will be available based on changes in initial outcomes.
When the data will become available and for how long
Start of access period 6 months after production and publication of results
To whom data/document is available
People engaged in research in medical universities of the country
Under which criteria data/document could be used
The methods and data contained in this clinical trial should be used solely to advance similar projects. It is also necessary to mention the research center of this study (Fasa University of Medical Sciences) if information is used
From where data/document is obtainable
Dr. Seyyed Amin Kouhpayeh Email address: kouhpayeha@gmail.com Contact number: 09177087247 Address: Department of Pharmacology, Fasa University of Medical Sciences and Health Services, Fasa, Iran. Email Address: Amindakhiliardestani@yahoo.com Contact number: 09228584505 Address: Fasa University, Fasa University of Medical Sciences and Health Services, Fasa, Iran.
What processes are involved for a request to access data/document
1. Contact the scientific or general respondent of the study 2. Sending their official request to the respondent 3. Apply to the University Research Council 4. In case of a positive response from the council, it will be provided to the applicant in accordance with the ethical principles. 5. The total duration of the process from the time of receiving the request is 20 days.
Comments
Loading...